Ophthalmological side effects of antipsychotic agents;Effetti indesiderati a carico dell'occhio e della funzione visiva dei farmaci antipsicotici

Minerva Psichiatrica

Volumn 47, Issue 2, 2006, Pages 129-142

  Fornaro, M ^a   Venuti, S ^a   Pompei, F ^a   Gabrielli, F ^a   Fornaro, P ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Antipsychotic agents; Degenerative retinopathies; Dopaminergic D4 receptors; Ophthalmology

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORPROMAZINE; CLOZAPINE; DOPAMINE RECEPTOR; NEUROLEPTIC AGENT; PHENOTHIAZINE; SEROTONIN 1D AGONIST; SEROTONIN 2A ANTAGONIST; THIORIDAZINE;

ACCOMMODATION PARALYSIS; ANTICHOLINERGIC EFFECT; BLEPHAROSPASM; CATARACT; CENTRAL NERVOUS SYSTEM; CLINICAL ASSESSMENT; GLAUCOMA; HUMAN; MYDRIASIS; OCULOGYRIC CRISIS; PHOTORECEPTOR; PIGMENT DISORDER; PIGMENT EPITHELIUM; RETINOPATHY; REVIEW;

EID: 33748784350     PISSN: 03911772     EISSN: 18271731     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Fornaro P, Venuti S, Fornaro M, Sartore F, Gabrielli F. Effetti oftalmologici indesiderati dei farmaci antidepressivi, ansiolitici e stabilizzatori del tono dell'umore. Minerva Psichiatr 2005;46:301-13.
2. Lieberman E, Stoudemire A. Use of tricyclic antidepressants in patients with glaucoma: assessment and appropriate precautions. Psychosomatics 1987;28:145-8.
3. Malone DA, Camara EG, Krug JH Jr. Ophthalmological effects of psychotropic medications. Psychosomatics 1992;3:271-7.
4. Oshika T. Ocular adverse effects of neuropsychiatric agents. Incidence and management. Drug Saf 1995;12:256-63.
5. Howard RO, Mc Donald CJ, Dunn B, Creasy WA. Experimental chlorpromazine cataracts. Invest Ophthalmol 1969;8:413-21.
6. Isaac NE, Walter AM, Jick H, Gorman M. Exposure to phenothiazine drugs and risk of cataract. Arch Ophthalmol 1991;109:256-60.
7. Shahzad S, Suleman MI, Shahab H, Mazour I, Kaur A, Rudzinskiy P et al. Cataract occurrence with antipsychotic drugs. Psychosomatics 2002;43:354-9.
8. Chiou GC. Ocular hypotensive actions of haloperidol, a dopaminergic antagonist. Arch Ophthalmol 1984;102:143-5.
9. Chiou GC. Treatment of ocular hypertension and glaucoma with dopamine antagonists. Ophthalmic Res 1984;16:129-34.
10. Mathalone MBR. Eye and skin changes in psychiatric patients treated with chlorpromazine. Br J Ophthalmol 1967;51:86-93.
11. Barsa JA, Newton JS, Saunders J. Lenticular and corneal opacities during phenothiazine therapy. JAMA 1965;193:98-100.
12. Kassman T, Wettenberg L. Lens opacities and porphobilinogen-like substance in urine associated with levomepromazine. Acta Psychiatr Scand 1907;43:163-8.
13. Fraunfelder FT. Drug-Induced Ocular Side Effects and Drug Interactions. Philadelphia: Lea & Febiger; 1976.
14. Forrest FM, Snow HL. Prognosis of eye complications caused by phenothiazines. Dis Nerv Syst 1968;29 Suppl:26-8.
15. Pouget R, Blayvac B. [Corneal and lens deposits due to treatment bv phenothiazine type neuroleptics] Ann Med Psychol (Paris) 1976;1:403-7. French.
16. Hesse RI. Anterior lens opacities in prolonged phenothiazine therapy. Ann Ophthalmol 1979;11:1212.
17. Delong SL. Incidence and significance of chlorpromazine-induced eye changes. Dis Nerv Syst 1968;29 Suppl:19-22.
18. Prien RF, Delong SL, Cole JO, Levine J. Ocular changes occuring with prolonged high dose chlorpromazine therapy. Arch Gen Psychiatry 1970;23:464-8.
19. th ed. Springfield: Charles C. Thomas; 1993.
20. Klein DF, Gittelman R, Quitkin F. Diagnosis and drug treatment of psychiatric disorders. Baltimore: Williams & Wilkins; 1980.
21. Bond WS, Yee GC. Ocular and cutaneous effects of chronic phenothiazine therapy. Am J Hosp Pharm 1980;37:74-8.
22. Cremer-Bartels G, Hollwich F. [The combination of light and phenothiazine effect on the incorporation of 14G-glucosamine in glycosaminoglycans in bovine cornea in vitro] Klin Monatsbl Augenheilkd 1974;164:134-7. German.
23. Menon IA, Basu PK, Hasany SM, Persad SD. Effects of UV-visible irradiation of rabbit cornea in the presence of chlorpromazine. J Toxicol Cutaneous Ocul Toxicol 1987;6:345-55.
24. Nouri A, Cuendet JF. Ocular side effects in the course of prolonged treatment with neuroleptics. Schweiz Med Wochenschr 1968;98:1708-11.
25. Garner LL, Wang RI, Hieb E. Eye changes following phenothiazine administration. Wis Med J 1974;73:S119-21.
26. Margolis L, Goble F. Lenticular opacities with prolonged phenothiazine therapy. JAMA 1965;193:95-7.
27. Edler K, Gottfries CG, Haslund J, Ravn J. Eye changes in connection with neuroleptic treatment especially concerning phenothiazines and thioxanthenes. Acta Psychiatr Scand 1971;47:377-84.
28. th Annual Meeting of the American College of Neuropsychopharmacology. Nashville, TN: ACNP; 1999.
29. Valibhai F, Still DJ, True J. Cataracts and quetiapine. Am J Psychiatry 2001;158:6.
30. Seroquel Package Insert. Wilmington, DE: Zeneca Pharmaceuticals; 2001.
31. th Annual Meeting of the American College of Neuropsychopharmacology. Nashville, TE: ACNP; 2000.
32. Prior T, Chue P, Tibbo P. Oral glucose challenge test abnormalities with atypical antipsychotics use. Schizophr Res 1999;36:357-8.
33. Zyprexa Package Insert. Indianapolis: Eli Lilly and Co; 2001.
34. Geodon (ziprasidone). In: Physicians' Desk Reference. 56th ed. Montvale, NJ: Medical Economics Co; 2002. p. 2688-92.
35. Thaler JS, Curinga R, Kiracofe G. Relation of graded ocular anterior chamber pigmentation to phenothiazine intake in schizophrenics-quantification procedures. Am J Optom Physiol Optics 1985;62:600-4.
36. Oshika T, Itotagawa K, Sawa M. Severe corneal edema after prolonged use of psychotropic agents. Cornea 1991;10:354-7.
37. Nishida K, Ohashi Y, Kinoshita S, Kiritoshi A, Manabe R. Endothelial decompensation in a schizophrenic patient receiving long-term treatment with tranquilizers. Cornea 1992;11:475-8.
38. Hull DS, Csukas S, Green K. Chlorpromazine-induced corneal endothelial phototoxicity. Invest Ophthalmol Vis Sci 1982;22:502-8.
39. Ramos AE, Shytle RD, Silver AA, Sanberg PR. Ziprasidone-induced oculogyric crisis. J Am Acad Child Adolesc Psychiatry 2003;42:1013-4.
40. Fornaro P. Aspetti iatrogeni della psicofarmacoterapia. In: Rossi R, Cartelli G, Bucca M editors. Igiene mentale. Psichiatria e prevenzione. Scandicci (FI): La Nuova Italia editrice; 1996. p. 169-82.
41. Nordström A-L, Farde L, Wiesel F-A, Forslund K, Pauli S, Halldin C et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33:227-35.
42. Casey DE, Keepers GA. Neuroleptics side effects: acute extrapyramidal syndromes and tardive diskinesia. Psychopharmacol Ser 1988;5:74-93.
43. Karson CN. Spontaneous eye-blink rates and dopaminergic systems. Brain 1983:106 (Pt 3):643-53.
44. Fornaro P, Placidi GF, Cavallacci G, Perossini M, Castrogiovanni P. L'elettroretinografia come possibile metodo di studio dell'attività dopaminergica nell'uomo. Rivista di Psichiatria 1980;1:115-8.
45. Fornaro P, Castrogiovanni P, Dell'Osso L, Perossini M, Placidi GF, Tassi G. Electroretinography (ERG) as a tool of investigation on dopaminergic activity in man. ERG changes induced by perphenazine and bromocriptine. Res Commun Psychol Psychiatr Behav 1984;9:307-23.
46. Gross-Isseroff R, Magen A, Shiloh R, Hermesh H, Weizman A. The 5-HT1D receptor agonist zoomitriptan for neuroleptic-induced akathisia: an open label preliminary study. Int Clin Psychopharmacol 2005;1:23-5.
47. Jankovic J, Orman J. Blepharospasm: demographic and clinical survey of 250 patients. Ann Ophthalmol 1984;16:371-6.
48. FitzGerald PM, Jankovic J. Tardive oculogyric crises. Neurology 1989;39:1434-7.
49. Tan CH, Chiang PC, Ng LL, Chee KT. Oculogyric spasm in Asian psychiatric inpatients on maintenance medication. Br J Psychiatry 1994;165:381-3.
50. Sachdev P, Tang WM. Psychotic symptoms preceding ocular deviation in a patient with tardive oculogyric crises. Aust N Z J Psychiatry 1992;26:666-70.
51. Sachdev P. Tardive and chronically recurrent oculogyric crises. Mov Disord 1993;8:93-7.
52. Yamaguchi N, Nakai H. Attacks of altered perception in schizophrenics. In: Uchiyaura Y editor. Psychopathology of Schizophrenia. Tokio: Tokio University Press; 1985. p. 295-314.
53. Higuchi H, Shimizu T, Hishikawa Y. Recurrent paroxysmal episodes characterized by perceptual alteration in three schizophrenic patients on neuroleptic medication. Psychiatry Clin Neurosci 1997;51:99-101.
54. Watanabe K. [The syndromes of oculogyric crisis and paroxysmal perceptual alteration in chronic schizophrenic patients clinical inquiry into their pathophysiology] Seishin Shinkeigaku Zasshi 1991;93:151-89. Japanese.
55. Horiguchi J, Inami Y. Effect of clonazepam on neuroleptic-induced oculogyric crisis. Acta Psychiatr Scand 1989;80:521-3.
56. Lee MS, Fern AI. Fluphenazine and its toxic maculopathy. Ophthalmic Res 2004;36:237-9.
57. Petrohelos MA, Tricoulis D. Ocular complications of Chlorpromazine therapy. Ophthalmologica 1969;159 Suppl:31-8.
58. Reboton J JR, Weekley RD, Bylenga ND, May RH. Pigmentary retinopathy and irido-cycloplegia in psychiatric patients. J Neuropsychiatry 1962;3:311-6.
59. Weekley RD, Potts AM, Reboton J Jr, May H. Pigmentary retinophaty in patients receiving high doses of a new phenothiazine. Arch Ophthalmol 1960;64:65-76.
60. Heshe J, Engelstoft FH, Kirk L. [Retinal injury developing under thioridazine treatment] Nord Psykiatr Tidsskr 1961;15:442-7. Danish.
61. De Margerie J. Ocular changes produced by a phenothiazine drug: thioridazine. Trans Can Ophthalmol Soc 1962;25:160-5.
62. Cameron ME, Lawrence JM, Obrich JG. Thioridazine (Mellaril) retinopathy. Br J Ophthalmol 1978;58:131-4.
63. Davidorf FM. Thioridazine pigmentary retinopathy. Arch Ophthalmol 1973;90:251-5.
64. Potts AM. Drug induced macular disease. Opthalmology 1970;70:1054-7.
65. Potts AM. Uveal pigment and phenothiazine compounds. Trans Am Ophthalmol Soc 1962;60:517-52.
66. Meier-Ruge W, Cerletti A. On experimental pathology of phenothiazine retinopathy. Ophthalmologica 1966;151:512-33.
67. Fornaro P, Perossini M, Paterra N. Retinopatie degenerative da fenotiazine: possibile ruolo patogenetico dell'azione dopaminolitica dei neurolettici. Rivista Sperimentale di Freniatria 1985;4:751-9.
68. Fornaro P, Calabria G, Corallo G, Picotti GB. Pathogenesis of degenerative retinopathies induced by thioridazine and other antipsychotics: a dopamine hypothesis. Doc Ophthalmol 2002;105:41-9.
69. Perossini M, Fornaro P. Electroretinographic effects induced in humans by psychopharmacological agents. Doc Ophthalmol 1990;75:1-9.
70. Kramer SG. Dopamine: a retinal neurotransmitter. I. Retinal uptake, storage and light-stimulated release of 3H-Dopamine in the retina in vivo. Invest Ophthalmol 1971;10:438-452.
71. Cohen AI, Todd RD, Harmon S, O'Malley KL. Photoreceptors of mouse retinal possess D4 receptors coupled to adenylate cyclase. Proc Natl Acad Sci USA 1992;89:12093-7.
72. Tran VT, Dickman M. Differential localization of Dopamine D1 and D2 receptors in rat retina. Invest Ophthalmol Vis Sci 1992;33:1620-6.
73. Filip V, Balik J. Possible indication of dopaminergic blockade in man by electroretinography. Int Pharmacopsychiatry 1978;13:151-6.
74. Bartel P, Blom M, Robinson E, Van der Meiden C, Sommers D, Becker P. The effects of levodopa and haloperidol on flash and pattern ERG and VEPs in normal humans. Doc Ophthalmol 1990;76:55-64.
75. Botermans CHG. Primary pigmentary degeneration and its association with neurological diseases. In: Vinken PJ, Bruyn GW editors. Neuroretinal degenerations. Amsterdam: North-Holland; 1972. p. 148-340.
76. Zinn KM, Marmor MF. Toxicology of the human retinal pigment epithelium. In: Zinn KM, Marmor MF editors. The retinal pigment epithelium. Cambridge, MA: Harvard University Press; 1979. p. 395-412.
77. Connell MM, Poley BJ, Mc Farlane JR. Chorioretinopathy associated with Thioridazine therapy. Arch Ophthalmol 1964;71:816-21.
78. Lam RW, Remick RA. Pigmentary retinopathy associated with low dose thioridazine treatment. Can Med Assoc J 1985;132:737.
79. Nguyen-Legros J, Chanut E, Versaux-Botteri C, Simon A, Trouvin JH. Dopamine inhibits melatonin synthesis in photoreceptor cells through a D2-like receptor subtype in the rat retina: biochemical and histochemical evidence. J Neurochem 1996;67:2514-20.
80. th Symposium, 1995, June 5-9, Athens, Greece.
81. Zawilska JB, Nowak JZ. Dopamine D4-like receptors in vertebrate retina: does the retina offer a model for the D4 receptors analysis?. Pol J Pharmacol 1997;49:201-11.
82. Tosini G, Dirden JC. Dopamine inhibits melatonin release in the mammalian retina: in vitro evidence. Neurosci Lett 2000;286:119-22.
83. Nowak JZ, Kazula A, Golembiowska K. Melatonin increases serotonin-N-acetyltransferase activity and decreases dopamine synthesis in light-exposed chick retina: in vivo evidence supporting melatonin-dopamine interaction in retina. J Neurochem 1992;59:1499-502.
84. Cheze G, Ali MA. [Role of the epiphysis in the migration of the retinal epithelial pigment in some teleosts] Can J Zool 1976;54:475-81. French.
85. Pang SF, Yew DT. Pigment aggregation by melatonin in the retinal pigment epithelium and choroids of guinea pigs 'Cavia porcellus'. Experientia 1979;35:231-3.
86. Pierce ME, Besharse JC. Circadian regulation of retinomotor movements. Interaction of melatonin and dopamine in the control of cone length. J Gen Physiol 1985;86:671-89.
87. Bersharse JC, Dunis DA. Rod photoreceptor disc shedding in eye cups: relationship to bicarbonate and aminoacids. Exp Eye Res 1983;36:567-80.
88. Weichman AF, O'Steen WK. Melatonin increases photoreceptor susceptibility to light damage. Invest Opthalmol Vis Sci 1992;33:1894-902.
89. Seeman P, Van Tol HH. Dopamine receptor pharmacology. Trends Pharmacol Sci 1994;15:265-70.
90. Sugawara T, Sieving PA, Iuvone PA, Bush R. The melatonin antagonist luzindole protects retinal photoreceptors from light damage in the rat. Invest Opthalmol Vis Sci 1998;12:2458-65.
91. Shibasaki H, Kato M, Inomata H, Nishimura M, Arakawa T, Kobayashi T et al. Pigmentary degeneration of the retina in heredodegenerative neurological diseases. Acta Neurol Scand 1979;59:331-42.
92. Wise JPH, Lorscheider FL. Low retinal dopamine and serum prolactin levels indicate an inherited dopaminergic abnormality in BW rats. Exp Eye Res 1981;32:541-51.
93. Ellis CJK, Allen TGJ, Marsden CD, Ikeda H. Electroretinographic abnormalities in idiopathic Parkinson's disease and the effect of levodopa administration. Clin Vis Sci 1987;1:347-55.
94. Brunello N. Meccanismi molecolari nell'azione dei nuovi farmaci antipsicotici. Quaderni Psichiatria 1999;3:15-23.
95. Matsumoto M, Midaka K, Tada S, Tasaki Y, Yamaguchi J. Full length DNA and distribution of human dopamine D4 receptor. Mol Brain Res 1995;29:157-62.
96. Cervetto L, Demontis GC, Giannaccini G, Longoni BM, Macchia B, Macchia R et al. N-n-Propyl-substituted 3-(dimethylphenyl) piperidines display novel discriminative properties between dopamine receptor subtypes: synthesis and receptor binding studies. J Med Chem 1998;41:4933-8.
97. Djamgoz MBA, Hankins MW, Hirano J, Archer R. Neurobiology of retinal dopamine in relation to degenerative states of the tissue. Vision Res 1997;24:3509-29.